O'Brien Greene & Co’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.15M | Sell |
8,543
-10
| -0.1% | -$2.15K | 0.59% | 35 |
|
|
2026
Q1 | $1.86M | Sell |
8,553
-155
| -2% | -$34.4K | 0.53% | 36 |
|
|
2025
Q4 | $1.99M | Sell |
8,708
-150
| -2% | -$34.2K | 0.59% | 37 |
|
|
2025
Q3 | $2.05M | Sell |
8,858
-1,916
| -18% | -$390K | 0.63% | 35 |
|
|
2025
Q2 | $2M | Sell |
10,774
-1
| -0% | -$186 | 0.65% | 36 |
|
|
2025
Q1 | $2.26M | Sell |
10,775
-189
| -2% | -$36.7K | 0.76% | 33 |
|
|
2024
Q4 | $1.95M | Buy |
10,964
+99
| +0.9% | +$18.2K | 0.63% | 37 |
|
|
2024
Q3 | $2.15M | Sell |
10,865
-1,396
| -11% | -$261K | 0.67% | 36 |
|
|
2024
Q2 | $2.1M | Sell |
12,261
-7,337
| -37% | -$1.22M | 0.67% | 34 |
|
|
2024
Q1 | $3.57M | Sell |
19,598
-25
| -0.1% | -$4.31K | 1.17% | 31 |
|
|
2023
Q4 | $3.04M | Sell |
19,623
-45
| -0.2% | -$6.56K | 1.07% | 32 |
|
|
2023
Q3 | $2.93M | Sell |
19,668
-147
| -0.7% | -$21.6K | 1.07% | 32 |
|
|
2023
Q2 | $2.67M | Buy |
19,815
+106
| +0.5% | +$15.5K | 0.93% | 34 |
|
|
2023
Q1 | $3.14M | Sell |
19,709
-25
| -0.1% | -$3.82K | 1.18% | 31 |
|
|
2022
Q4 | $3.19M | Sell |
19,734
-40,956
| -67% | -$6.28M | 1.21% | 30 |
|
|
2022
Q3 | $8.14M | Buy |
60,690
+40,464
| +200% | +$5.81M | 1.08% | 30 |
|
|
2022
Q2 | $3.1M | Hold |
20,226
| – | – | 1.17% | 33 |
|
|
2022
Q1 | $3.28M | Sell |
20,226
-57
| -0.3% | -$8.28K | 1.08% | 33 |
|
|
2021
Q4 | $2.75M | Buy |
20,283
+167
| +0.8% | +$19.7K | 0.9% | 33 |
|
|
2021
Q3 | $2.17M | Buy |
20,116
+75
| +0.4% | +$8.57K | 0.79% | 34 |
|
|
2021
Q2 | $2.26M | Buy |
20,041
+175
| +0.9% | +$19.7K | 0.81% | 36 |
|
|
2021
Q1 | $2.15M | Hold |
19,866
| – | – | 0.85% | 34 |
|
|
2020
Q4 | $2.13M | Buy |
19,866
+5,953
| +43% | +$572K | 0.88% | 36 |
|
|
2020
Q3 | $1.22M | Sell |
13,913
-178
| -1% | -$16.8K | 0.58% | 42 |
|
|
2020
Q2 | $1.38M | Sell |
14,091
-30
| -0.2% | -$2.64K | 0.73% | 39 |
|
|
2020
Q1 | $1.08M | Sell |
14,121
-165
| -1% | -$14.1K | 0.72% | 39 |
|
|
2019
Q4 | $1.26M | Sell |
14,286
-2,350
| -14% | -$195K | 0.64% | 40 |
|
|
2019
Q3 | $1.26M | Sell |
16,636
-50
| -0.3% | -$3.43K | 0.68% | 41 |
|
|
2019
Q2 | $1.21M | Sell |
16,686
-397
| -2% | -$31.2K | 0.64% | 42 |
|
|
2019
Q1 | $1.38M | Buy |
17,083
+2,025
| +13% | +$166K | 0.69% | 40 |
|
|
2018
Q4 | $1.39M | Buy |
+15,058
| New | +$1.32M | 0.83% | 41 |
|
Other funds holding ABBV
O'Brien Greene & Co's ABBV Position: Q2 2026 in Review
O'Brien Greene & Co reduced its AbbVie (ABBV) stake by 0.12% in Q2 2026, selling an estimated $2.15K and leaving 8,543 shares worth $2.15M. The position accounts for 0.59% of the portfolio, ranked #35.
O'Brien Greene & Co first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $8.14M in Q3 2022. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- O'Brien Greene & Co held 8,543 shares of AbbVie worth $2.15M as of Q2 2026.
- O'Brien Greene & Co sold 10 AbbVie shares in Q2 2026, an estimated $2.15K.
- AbbVie made up 0.59% of O'Brien Greene & Co's portfolio in Q2 2026, its #35 holding.
- O'Brien Greene & Co first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- O'Brien Greene & Co's AbbVie position peaked at $8.14M in Q3 2022.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on O'Brien Greene & Co's 13F filing for Q2 2026, filed 6 Aug 2026.